Navigation Links
Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research

have not received prior chemotherapy for advanced disease.

Head and Neck Cancer

Taxotere(R) in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with inoperable locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Important safety information

WARNING: Taxotere(R) treatment can cause serious, physically limiting, and potentially life-threatening side effects, such as infection, low blood-cell counts, allergic reaction and retention of excess fluid (edema).

Taxotere(R) in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic NSCLC who have not previously received chemotherapy for this condition.

Taxotere(R) should not be given to patients with low white-blood-cell counts, abnormal liver function, or a history of allergic reactions to Taxotere(R) or any of the ingredients in Taxotere(R).

Before each Taxotere(R) treatment, all patients treated with Taxotere(R) must receive another medicine called dexamethasone. This drug can help reduce the risk of fluid retention (edema) and allergic reactions.

Taxotere(R) should be administered only under the supervision of a qualified physician experienced in the use of anticancer treatments. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available.

Treatment-related acute myeloid leukemia (AML) has occurred in patients given anthracyclines and/or cyclophosphamide, including use with Taxotere(R) in adjuvant therapy for breast cancer. The most common severe side effects are low white-blood-cell count, anemia, fatigue, diarrhea, and mouth and throat irritation. Low white-blood-cell count can lead to life-threatening infections. The earliest sign of infection may be fever, so tell your doctor right away if you have a fever. Other common side effects from Taxotere(R) include
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:4/27/2015)... April 27, 2015 Numerous Zofran birth defects ... the U.S. have highlighted serious concerns surrounding the use ... According to the U.S. Centers for Disease Control ... the market have enough information to determine their safety ... expectant mothers in the U.S. take at least one ...
(Date:4/27/2015)... NEW YORK , April 27, 2015   ... management solutions, will showcase advances in monitored care that ... the upcoming ATA 2015 Conference, May 2-5 ... Center. AMC Health will share information about ... monitored care to help transform and personalize healthcare delivery ...
(Date:4/27/2015)... Pa. , April 27, 2015  SCILEX ... and commercialization of products focused on the treatment ... team of William Stewart and ... important steps in SCILEX,s proprietary drug development program ... its products. The Company,s first product, ZTlido™ (lidocaine ...
Breaking Medicine Technology:Growing Zofran Birth Defects Litigation Highlights Concerns Surrounding Use of Prescription Medications During Pregnancy, According to Bernstein Liebhard LLP 2Growing Zofran Birth Defects Litigation Highlights Concerns Surrounding Use of Prescription Medications During Pregnancy, According to Bernstein Liebhard LLP 3AMC Health to Showcase Advances in Monitored Care at ATA 2015 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 3AMC Health to Showcase Advances in Monitored Care at ATA 2015 4SCILEX Pharmaceuticals Announces Commercial Executive Appointments 2SCILEX Pharmaceuticals Announces Commercial Executive Appointments 3
(Date:4/27/2015)... "Understanding Mental Disorders: Your Guide to the ... Psychiatric Publishing, a division of the American Psychiatric Association. ... National Press Club in Washington, D.C.. The launch event ... President Paul Summergrad, MD. Guest speakers will include Former ... the book; Paul Gionfriddo, President and CEO of Mental ...
(Date:4/27/2015)... CA (PRWEB) April 27, 2015 On April ... to Get Rid of Stretch Marks ,” interviewed a ... marks . Stretch marks are a type of ... marks are caused by a breakdown of the elsastin and ... epidermis. (see: goo.gl/iRdmEe) , “Stretch mark removal with the ...
(Date:4/27/2015)... Beckman Coulter is sponsoring a ... the evolution of neural circuitry and swimming behavior of ... mechanisms by which analogous forms of swimming behavior, such ... independently in certain sea slug clades. The webinar is ... 30, 2015 at 8:00am PT. , Sea slugs (Mollusca, ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Sitting or standing ... ache and feel tired, and for those whose occupation requires ... receptionists and taxi cab drivers, or to be on their ... hairdressers, the discomfort can be more severe and longer lasting. ... leg syndrome. Dr. Madaiah Revana of Northeast Houston Vein Center ...
(Date:4/27/2015)... FMC Corporation’s Health and Nutrition business announced ... market leading ingredients and solutions at Vitafoods Europe from ... Europe 2015 expects to host 14,000 attendees and 750 ... in such areas as digestive health, heart health, healthy ... Nutrition’s booth will feature its world leading Epax® brand ...
Breaking Medicine News(10 mins):Health News:American Psychiatric Association, Patrick Kennedy To Debut New Consumer Guidebook “Understanding Mental Disorders” 2Health News:Stretch Marks: The Latest Treatment Options for Stretch Mark Removal 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 3Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 3Health News:FMC Health and Nutrition to Feature Epax® Brand Omega-3 Ingredients at Vitafoods Europe 2015 2
... The developer of a product, known as ALKA-V6, a ... research as a potential cancer fighting weapon, has been named ... Arts at Texas State University. , Ignacius Cisneros, of Odessa, ... Alumni and business leaders. , In inviting Cisneros to participate, ...
... ... their shut-off products in an industrial gray color. , ... Loveland, CO (Vocus) October 30, 2009 -- Kent Systems is now ... offered were in patriotic red, white, and blue as well as black. The color selections ...
... , ... analyzes myths concerning alpine skiing injuries , ... Rosemont, IL (Vocus) October 30, 2009 -- Alpine skiing is ... crash videos replayed during the evening sports casts. However, a new study published in ...
... Findings from a new retrospective cohort study presented at ... in San Diego indicate that patients with Inflammatory Bowel ... medications to treat IBD, may be at risk for ... of the University of North Carolina, Chapel Hill, and ...
... ... increase the efficiency of inactivating 99.9% of the flu virus. The filter has been ... extracts. , ... CA (PRWEB) October 29, 2009 -- Coway ,s new anti-flu air filter ...
... 29 The Ensign Group, Inc. (Nasdaq: ENSG ... skilled nursing, rehabilitative care services, hospice care and assisted ... the Oppenheimer & Co. 20th Annual Healthcare Conference on ... (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ) , Christopher Christensen, the ...
Cached Medicine News:Health News:Texas State University Names Developer of ALKA-V6 Compound to Board of Advisors 2Health News:Skiing Not As Dangerous as Believed 2Health News:Skiing Not As Dangerous as Believed 3Health News:Skiing Not As Dangerous as Believed 4Health News:Study reveals possible link between IBD therapy and skin cancer 2Health News:Coway Announces New Anti-Flu Air Filter Can Inactivate 2009 Seasonal Flu Virus 2Health News:The Ensign Group to Present at Oppenheimer 20th Annual Healthcare Conference 2
Double Ended Occluders...
Long handle occluders are approximately 9 inches long....
Manual Lensmeter....
Lightweight, cordless lensmeter....
Medicine Products: